TL;DR: Curaleaf Q3 2026 results confirm operational discipline in a compressed pricing environment. With cost reductions flowing through the P&L and a refreshed retail portfolio, CURLF is building the foundation for meaningful margin expansion — contingent on Schedule III delivering expected 280E relief before year-end. Check the cannabis stock tracker for live CURLF pricing and sector context.
Q3 2026 Earnings Overview
Curaleaf Holdings entered Q3 2026 earnings season as the largest publicly traded multi-state operator by retail footprint. Revenue for the quarter came in near $316 million, modestly below consensus estimates of $322 million, as wholesale price compression across Florida, Pennsylvania, and New Jersey offset gains in higher-margin adult-use states including Ohio and Maryland.
Adjusted EBITDA improved to approximately $72 million, a 22.8% margin. While still below the 25–28% target range, the sequential improvement signals that the cost optimization initiative launched in Q1 2026 is working. Curaleaf closed or converted 14 underperforming retail locations during the quarter, bringing its North American store count to 147, down from a peak of 162 in mid-2025.
Gross margin held at approximately 47%, a key stabilization point. The company has reduced SKU complexity in states where in-house cultivation supports both retail and wholesale, and the margin defense in core markets like Florida — where adult-use legislation remains stalled — speaks to operational maturity that many peers have not yet achieved.
State-by-State Performance Drivers
Ohio remains Curaleaf’s most strategically significant Q3 story. The adult-use market — operational since August 2024 — continued its ramp, with CURLF’s Columbus and Cleveland metro positioning contributing disproportionately to sequential revenue improvement. Ohio adult-use transactions per store per day increased 18% quarter-over-quarter, outpacing the state average and reflecting dispensary locations in established medical footprint corridors.
Pennsylvania medical remains a drag. Price compression in medical-only markets, combined with adult-use legislative uncertainty, constrained contribution from the Commonwealth’s 22 Curaleaf locations. Maryland adult-use offset this: CURLF’s six Maryland stores averaged $1.4 million monthly in Q3, with edibles and pre-roll categories leading volume growth.
International operations through EMMAC contributed approximately $18 million in Q3 revenue. Germany’s emerging medical framework provides incremental growth visibility and a valuation diversification argument that is increasingly relevant as European regulatory frameworks mature.
280E Relief: The Central Investment Thesis
The core investment thesis for CURLF at current levels is tax normalization, not organic revenue growth. Curaleaf paid approximately $38 million in federal income taxes under 280E through the first three quarters of 2026 — a cash burden that depresses free cash flow and makes debt management far more complex than it would be for any comparable non-cannabis retailer.
A Schedule III final rule — projected by the DEA’s administrative timeline for Q1 2027 — would eliminate 280E applicability for schedule III substances. Removing that quarterly tax burden on $316 million in revenue would be transformative for FCF generation and balance sheet deleveraging. Curaleaf carries approximately $570 million in long-term debt, and management has signaled aggressive debt reduction contingent on 280E resolution.
Curaleaf’s revenue concentration in high-margin adult-use states — Ohio, Maryland, New Jersey — means the incremental FCF capture from 280E relief would be among the largest in absolute dollar terms across the sector. This benefit accrues disproportionately to operators with the highest effective tax rates relative to EBITDA, a category where CURLF is well-positioned.
Forward Outlook
Management guided Q4 2026 revenue to $310–325 million, reflecting seasonal patterns: a modest October dip as summer demand normalizes, offset by holiday quarter uplift in December. The guidance range is conservative with upside from Ohio and Maryland outperformance, a recurring pattern through 2026.
The critical variable for CURLF’s 2027 setup remains the Schedule III timeline. A Q1 2027 final rule would deliver materially improved FCF, a leaner retail footprint, and sector-leading adult-use market exposure simultaneously. At current CURLF prices, that optionality is not fully reflected in consensus estimates. Monitor the cannabis stock tracker for real-time CURLF price action as the rescheduling timeline develops.